NewsNovo
(Nasdaq: VIVS) received a formal deficiency notice from Nasdaq's Listing Qualifications Staff on July 20, 2026, after the San Diego biotech's Form 10-K for the year ended March 31, 2026 showed stockholders' equity of negative $1,099,000, well below Nasdaq's $2.5 million minimum under Listing Rule 5550(b)(1).
The company simultaneously disclosed that its equity had already crossed back above that threshold, the result of three separate capital events that closed in rapid succession before the notice arrived.
The deficiency and its compliance clock Nasdaq's rule allows two remediation paths. VivoSim has until September 3, 2026 (45 calendar days from the notice date) to submit a compliance plan.
If Nasdaq accepts that plan, the company could receive up to 180 calendar days from July 20, 2026, extending the window to January 16, 2027, to demonstrate sustained compliance.
Keep reading